BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 29871978)

  • 1. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.
    Sharma A; Hijazi Z; Andersson U; Al-Khatib SM; Lopes RD; Alexander JH; Held C; Hylek EM; Leonardi S; Hanna M; Ezekowitz JA; Siegbahn A; Granger CB; Wallentin L
    Circulation; 2018 Oct; 138(16):1666-1676. PubMed ID: 29871978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
    Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
    Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
    Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Yusuf S; Granger CB; Siegbahn A; Wallentin L;
    Eur Heart J; 2018 Feb; 39(6):477-485. PubMed ID: 29069359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time.
    Hijazi Z; Lindahl B; Oldgren J; Andersson U; Lindbäck J; Granger CB; Alexander JH; Gersh BJ; Hanna M; Harjola VP; Hylek EM; Lopes RD; Siegbahn A; Wallentin L
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28645934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation.
    Hijazi Z; Wallentin L; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Granger CB; Lopes RD; Pol T; Yusuf S; Oldgren J; Siegbahn A
    J Am Heart Assoc; 2020 Dec; 9(24):e018984. PubMed ID: 33292046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
    Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
    JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
    Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
    Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy.
    Horowitz JD; De Caterina R; Heresztyn T; Alexander JH; Andersson U; Lopes RD; Steg PG; Hylek EM; Mohan P; Hanna M; Jansky P; Granger CB; Wallentin L;
    J Am Coll Cardiol; 2018 Aug; 72(7):721-733. PubMed ID: 30092948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.
    Oldgren J; Hijazi Z; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Granger CB; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Wallentin L;
    Circulation; 2016 Nov; 134(22):1697-1707. PubMed ID: 27569438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin.
    Vinereanu D; Lopes RD; Mulder H; Gersh BJ; Hanna M; de Barros E Silva PGM; Atar D; Wallentin L; Granger CB; Alexander JH;
    Stroke; 2017 Dec; 48(12):3266-3273. PubMed ID: 29089455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
    Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
    Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
    Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.
    Pol T; Held C; Westerbergh J; Lindbäck J; Alexander JH; Alings M; Erol C; Goto S; Halvorsen S; Huber K; Hanna M; Lopes RD; Ruzyllo W; Granger CB; Hijazi Z
    J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29419390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.